Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today on ...

Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactamFosmanogepix second phase 3 study initiated; two phase 3 studies in invasive fungal infecti ...

A few weeks ago, I had the pleasure of traveling through this beautiful country. Within just a few days, I left with the ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...